Zobrazeno 1 - 10
of 1 038
pro vyhledávání: '"Broggini, M."'
Autor:
Ganzinelli, M., Linardou, H., Alvisi, M.F., Caiola, E., Lo Russo, G., Cecere, F.L., Bettini, A.C., Psyrri, A., Milella, M., Rulli, E., Fabbri, A., De Maglie, M., Romanelli, P., Murray, S., Broggini, M., Marabese, M., Garassino, M.C.
Publikováno v:
In ESMO Open February 2021 6(1)
Publikováno v:
Cancer Management and Research, Vol Volume 11, Pp 10337-10344 (2019)
Oscar Corli,1 Giovanna Damia,2 Francesca Galli,3 Carmen Verrastro,4 Massimo Broggini2 1Unit of Pain and Palliative Care Research, Laboratory of Methodology for Clinical Research, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy; 2L
Externí odkaz:
https://doaj.org/article/68ff2e3ac076495c98fc737d74b000c6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Cancer Management and Research, Vol 2013, Iss default, Pp 15-20 (2013)
Massimo Broggini,1 Marina Chiara Garassino,2 Giovanna Damia11Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche "Mario Negri", 2Division of Medical Oncology, Fondazione IRCCS National Cancer Institute, Milan, ItalyAbstract: Tiv
Externí odkaz:
https://doaj.org/article/7ad4f96a9ce24585a5c69ca25bf33c0e
Background: Platinum-based therapy, combined or not with immune checkpoint inhibitors, represents a front-line choice for patients with non-small-cell lung cancer (NSCLC). Despite the improved outcomes in the last years for this malignancy, only a su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::9d2bcf501ec7d56b1e6f051ffd079130
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3077170
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3077170
Autor:
Marchini, S. *, Marabese, M., Marrazzo, E., Mariani, P., Cattaneo, D., Fossati, R., Compagnoni, A., Fruscio, R., Lissoni, A.A., Broggini, M.
Publikováno v:
In Annals of Oncology March 2008 19(3):501-507
Clinical data suggest that only a subgroup of non-small cell lung cancer (NSCLC) patients has long-term benefits after front-line platinum-based therapy. We prospectively investigate whether KRAS status and DNA polymerase β expression could help ide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::1528961d172db2fc857aee62c20f1254
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3104049
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3104049
Autor:
Arribas, A., Chiappa, M., Napoli, S., Cannas, E., Cascione, L., Spriano, F., Tarantelli, C., Rossi, D., Zucca, E., Alimonti, A., Stathis, A., Damia, G., Broggini, M., Bertoni, F.
Publikováno v:
In European Journal of Cancer October 2022 174 Supplement 1:S107-S108
Publikováno v:
In European Journal of Cancer January 2002 38(1):177-183
Publikováno v:
Pharmacogenomics Journal. Oct2014, Vol. 14 Issue 5, p401-410. 10p.